Final-Program-ATS-2023-AP.vp

132

MONDAY • MAY 22

Target Audience Providers of lung health, clinicians and researchers Objectives At the conclusion of this session, the participant will be able to: • identify the critical role the NCI Moonshot will play in cancer detection and treatment research for years to come • Recognize research gaps in detecting and treating lung cancer • identify ongoing efforts in tobacco control and early detection including screening and biomarkers to improve outcomes from lung cancer The ATS is a vital partner in NCI’s Cancer Moonshot. Lung cancer care and research will focus on efforts to reduce deaths from this deadliest of cancers through early detection and new molecularly driven diagnoses and targeted treatment. Taken directly from Moonshot version 2.0 the overarching themes of this symposium will focus on Expanding Use of Proven Cancer Prevention and Early Detection Strategies and Developing new enabling cancer technologies. Each speaker will discuss LC specific topics related to these themes including reducing disparities, increasing early detection and primary prevention, and the role of biomarkers along the continuum of care. Chairing: N.T. Tanner, MD, MSCR, Charleston, SC R.S. Wiener, MD, MPH, ATSF, Boston, MA M.P. Rivera, MD, ATSF, Rochester, NY 9:00 Introduction to the 2022 Reignition of the Cancer Moonshot S. Elnahal, MD, MBA, Washington, DC 9:15 Reducing Disparities Across the Lung Cancer Continuum: Expanding Use of Proven Early Detection Strategies M.C. Aldrich, MPH, PhD, Nashville, TN 9:33 Lung Cancer Screening: Harnessing the VA Enterprise to Expand Proven Early Detection Strategies C.G. Slatore, MD, Portland, OR 9:52 Tobacco Control and Treatment: A Major Key to Cancer Prevention A.C. Melzer, MD, MS, Minneapolis, MN 10:11 Precision Oncology for Lung Cancer: Developing New Enabling Cancer Technologies P. Nana-Sinkam, MD, Richmond, VA This session and the International Conference are supported by an independent medical educational grant from Merck & Co. All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

There are well-documented examples of sex-specific clinical features of many lung diseases. Yet, our understanding of how a patient’s sex influences lung disease pathogenesis remains limited. This symposium will cover recent breakthroughs in our understanding of lung disease enabled by the application of single-cell profiling technologies. This session reviews the current landscape of ARDS, cystic fibrosis, asthma, and COPD pathophysiology discoveries through the lens of single-cell profiling and the role of sex-specific contributions. As we review these recent breakthroughs, we will highlight the strengths and limitations of this approach and discuss emerging technologies that will shape the future of this field. Chairing: C.J. Britto-Leon, MD, ATSF, New Haven, CT J. Kropski, MD, Nashville, TN V. Krymskaya, PhD, MBA, Philadelphia, PA 9:00 Sex-Based Differences in Macrophage Transcriptional Heterogeneity in Acute Lung Injury K. Mould, MD, MPH, Denver, CO 9:15 Using Transcriptome Metanalysis to Uncover Sex-Specific Mechanisms of Asthma Pathogenesis S. Kay, MD, MS, New Haven, CT 9:30 The Sex-Specific Connectome of Airway Immune Cells in Cystic Fibrosis as a Determinant of Its Dimorphic Clinical Course C.J. Britto-Leon, MD, ATSF, New Haven, CT 9:45 Sex-Specific Pathogenic Cell Populations in the Fibrotic Lung J. Kropski, MD, Nashville, TN 10:00 Lung Spatial Profiling Reveals a Sex-Specific T Cell Signature in COPD Patients with Fatal SARS-CoV-2 Infection F. Polverino, MD, PhD, Houston, TX 10:15 Using the Human Cell Atlas’ discovAIR Project to Uncover Sex-Based Differences That Drive Lung Disease on a Large-Scale Speaker To Be Announced

CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

B10 REIGNITING THE CANCER MOONSHOT: ATS = MISSION CONTROL FOR LUNG CANCER Assembly on Thoracic Oncology; Tobacco Action Committee 9:00 AM - 10:30 AM Marriott Marquis Washington Marquis Ballroom Salon 6 (Level M2)

ATS 2023 • Washington, DC